# Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Study · id `cardio:ct-nct06360120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06360120](<https://clinicaltrials.gov/study/NCT06360120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06360120

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT06360120. Randomized; double masking; primary purpose treatment. Start 2024-04-10 (actual); primary completion 2025-09-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT06360120, source copy `cardio:ctgov-nct06360120-2025-09-05`, retrieved 2026-10-26)
- Started: 2024-04-10 (actual) (ClinicalTrials.gov record NCT06360120, source copy `cardio:ctgov-nct06360120-2025-09-05`, retrieved 2026-10-26)
- Primary completion: 2025-09-10 (anticipated) (ClinicalTrials.gov record NCT06360120, source copy `cardio:ctgov-nct06360120-2025-09-05`, retrieved 2026-10-26)
- Completion: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT06360120, source copy `cardio:ctgov-nct06360120-2025-09-05`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06360120, source copy `cardio:ctgov-nct06360120-2025-09-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06360120-2025-09-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke
- Condition: Ischemic Stroke
- Intervention (Drug): Atorvastatin 40 Mg Oral Tablet
- Intervention (Drug): Rosuvastatin 20mg
- Intervention (Drug): Clopidogrel 75 Mg Oral Tablet
- Intervention (Drug): Clopidogrel 75 Mg Oral Tablet
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: a66bfe4f7008df41c37ec9d35675c7e6868b4054ab1bf39eb63a703fecf2e5cb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
